Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Other hematologic neoplasm 1Genitourinary 1CNS 1Breast 1

Conditions

Sarcoma 2Tertiary Lymphoid Structures 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 20pembrolizumab 19Nivolumab 10fludarabine 7Radiosurgery 7Specimen Handling 6Ipilimumab 6Injections 5Celecoxib 5poly ICLC 4Radiation 4Paclitaxel 4Melphalan 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Docetaxel 4Cryosurgery 4durvalumab 3cemiplimab 3Filgrastim 3Etoposide 3Cisplatin 3Blood Specimen Collection 3Biopsy 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2bempegaldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × bintrafusp alfa protein, human × Sarcoma × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡